Active c-Abl can be inhibited by the small molecule drug imatinib (Gleevec; STI-571), which was developed against the aberrant BCR/Abl fusion protein found in chronic myeloid leukemia (CML) [8]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.